EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zenith Capital's enterprise value is C$20.15 Mil.
Zenith Capital's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was C$-21.40 Mil. Therefore, Zenith Capital's EV-to-EBITDA for today is -0.94.
The historical rank and industry rank for Zenith Capital's EV-to-EBITDA or its related term are showing as below:
TSXV:ZENI.P'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.33 Med: 0 Max: 0.1
Current: -0.94
During the past 6 years, the highest EV-to-EBITDA of Zenith Capital was 0.10. The lowest was -4.33. And the median was 0.00.
TSXV:ZENI.P's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.63
vs TSXV:ZENI.P: -0.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Zenith Capital EV-to-EBITDA Historical Data
The historical data trend for Zenith Capital's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zenith Capital's EV-to-EBITDA
For the Biotechnology subindustry, Zenith Capital's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenith Capital's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zenith Capital's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zenith Capital's EV-to-EBITDA falls into.
Zenith Capital EV-to-EBITDA Calculation
Zenith Capital's EV-to-EBITDA for today is calculated as:
Zenith Capital's current Enterprise Value is C$20.15 Mil.
Zenith Capital's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-21.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenith Capital (TSXV:ZENI.P) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zenith Capital's PE Ratio for today is calculated as:
Zenith Capital's share price for today is C$0.105.
Zenith Capital's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.147.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Zenith Capital's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:ZENI.P has been successfully added to your 